For months, the working assumption in the response to the Democratic Republic of the Congo's Ebola outbreak has been simple and grim: the world's two licensed Ebola vaccines target the wrong strain, and there is nothing on the shelf.
New laboratory data complicate that. Researchers tested blood from 179 West African adults and children who had received one of the two licensed Zaire Ebola vaccines and found measurable antibody activity against Bundibugyo virus, the strain driving the current outbreak. The findings were published in the New England Journal of Medicine and reported by CIDRAP.
This is not a finding that a vaccine works. It is a finding that an immune response exists. The distance between those two statements is the whole story, and it is the reason no agency has changed its guidance.
What the Antibody Data Actually Showed
Bundibugyo is one of six known Ebola species. The only licensed vaccines, Merck's Ervebo and the two-dose Zabdeno and Mvabea regimen from a Johnson & Johnson subsidiary, were developed against Zaire ebolavirus, the species responsible for the 2014 to 2016 West African epidemic.
Researchers took stored serum from people vaccinated with those products and measured whether their antibodies recognized Bundibugyo. They did, but weakly.
Three months after a single dose of Ervebo, the antibody response against Bundibugyo was roughly eight times lower than the response against Zaire. The Zabdeno and Mvabea regimen produced about six times more antibodies against Zaire than against Bundibugyo.
The authors noted that these results align with earlier work in nonhuman primates, and wrote that the Merck vaccine, already held in the global Ebola stockpile, "represents an immediately deployable candidate that could be evaluated during the ongoing outbreak."
That phrasing is deliberate. Evaluated, not deployed.
Why an Antibody Response Is Not the Same as Protection
This distinction gets flattened in most coverage, so it is worth being precise.
An antibody response measured in a laboratory assay tells you the immune system produced something that binds to the virus. It does not tell you how much of that response is needed to prevent infection, prevent severe disease or prevent death. That threshold is called a correlate of protection, and for Bundibugyo it has not been established.
A response six to eight times weaker than the response against the strain a vaccine was designed for could still be protective. It could also fall below whatever the protective threshold turns out to be. Nothing in this dataset resolves that.
There is also no efficacy trial. These were stored blood samples from people vaccinated for other reasons, not people exposed to Bundibugyo and followed for outcomes. No one has demonstrated that a vaccinated person is less likely to become ill with this strain.
For American readers, the practical relevance is indirect. Direct risk in the United States remains low, and this finding does not change that.
What This Changes Since Our Earlier Reporting
MedicalDaily has reported repeatedly that no approved vaccine exists for Bundibugyo, and that the World Health Organization had recommended against using the Zaire vaccines in this outbreak. That framing appeared in our coverage of the CDC's renewed travel restrictions and of the outbreak passing 1,000 deaths.
Both statements remain accurate. What has changed is that there is now published human immunological data where previously there was mainly animal data, and the study authors have explicitly raised stockpile deployment as an option worth evaluating.
That converts a closed question into an open one. Whether the WHO revisits its recommendation is now a live decision rather than a settled position.
The Argument Over Waiting for Better Evidence
Boghuma K. Titanji, MD, DTM&H, PhD, an infectious disease physician, argued in a commentary posted on the social platform Bluesky and relayed by CIDRAP that the data should prompt the WHO to reconsider deploying Zaire vaccine stockpiles. She noted that officials responding to outbreaks rarely have perfect evidence and must weigh uncertainty against the cost of delay.
"I do not think this outbreak affords us the luxury to wait much longer," she said.
Readers should weigh that appropriately. It is an individual expert's argument published on social media, not an agency position or a peer-reviewed conclusion, and MedicalDaily notes the format because it affects how much weight the comment carries.
The counterargument is real too. Deploying a vaccine of unproven benefit consumes doses, staff time and community trust in a response already short of all three, and a product that fails can make future campaigns harder.
Separately, a purpose-built option is moving. The University of Oxford's phase 1 trial of a Bundibugyo-specific vaccine candidate vaccinated its first volunteer this month, assessing safety and immune response in 50 healthy adults aged 18 to 55. A phase 1 trial answers safety and immunogenicity questions, not efficacy ones, and will not produce a licensed product during this outbreak.
What Happens Next
The decision point sits with the WHO and its advisory groups, which would need to determine whether an evaluation of stockpiled Ervebo in the current outbreak is justified. No timeline has been announced.
Case counts continue to move. Reported totals have differed between sources and dates as surveillance catches up, and the WHO has cautioned that confirmed figures understate actual transmission given gaps across a conflict-affected region. Readers tracking numbers should note the date attached to any figure.
The confirmed development is that licensed Zaire Ebola vaccines produce a measurable but substantially weaker antibody response against Bundibugyo. The most affected people are patients and health workers in northeastern DRC. The reasonable action for U.S. households is unchanged: no vaccination is indicated, and travelers to affected regions should follow current CDC guidance. The central uncertainty is whether that weaker response is strong enough to protect anyone.
Developing Story Timeline
July 2026: NEJM correspondence reports cross-reactive antibody responses against Bundibugyo in people vaccinated with licensed Zaire Ebola vaccines.
Mid-July 2026: The University of Oxford launches and doses the first volunteer in a phase 1 Bundibugyo vaccine trial.
July 2026: The CDC renews U.S. entry screening measures for travelers from affected countries.
February 2026: The outbreak that would become the largest recorded Bundibugyo event begins in the DRC.
Frequently Asked Questions
What did the study find? Blood from 179 West Africans vaccinated with licensed Zaire Ebola vaccines showed antibody activity against Bundibugyo virus, though six to eight times weaker than against Zaire.
Does this mean the vaccines work against Bundibugyo? No. The study measured antibodies in stored blood samples. It did not test whether vaccinated people are less likely to become infected or die.
Why does the strain matter? Ervebo and the Zabdeno and Mvabea regimen were designed against Zaire ebolavirus. Bundibugyo is a different species, and no licensed vaccine targets it.
Has the WHO changed its recommendation? No. The study authors suggested the stockpiled Merck vaccine could be evaluated during the outbreak. No agency has announced a change.
Is there a Bundibugyo-specific vaccine coming? A University of Oxford phase 1 trial began this month in 50 healthy adults. Phase 1 assesses safety and immune response, not effectiveness, and will not deliver a licensed product during this outbreak.
What is the risk to people in the United States? Low. No vaccination is indicated for the U.S. public. Travelers to affected countries should follow current CDC guidance and screening requirements.
Why do case counts differ between reports? Surveillance in the affected region is incomplete and figures are revised as data catch up. Any number should be read with its reporting date.
